CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM) J Bradley Elder , Simon Hanft , Ian Y Lee , Christopher Farrell , John A Boockvar , Brad E Zacharia , Lyndon Kim , Michael Schulder , Carlos Eduardo Silva Correia , Rohan Ramakrishna , Eric T Wong , Julian Wu , Vijay Agarwal , Nduka Amankulor , Ankush Bhatia , Linton T Evans , Cameron Brennan , Brian J Gill , Soma Sengupta , Alfredo Quiñones-Hinojosa , Pierre Giglio , Kyle Wu , Synphen H Wu , Cristina Falo , Tobias Walbert , Adam Robin , Iyad Alnahhas , Morana Vojnic , A Gabriella Wernicke , Dawit Aregawi , Robert Maurer , Saadi Ghatan , Samuel Singer , Suriya Jeyapalan , Rajiv Magge , Athar N Malik , Nitesh Patel , Amy Chan , Fabio Iwamoto , Adilia Hormigo , Dominique Higgins , Mahua Dey , Nelson S Moss , Wendy Sherman , Leila Neese , Gregory K Pennock , Charles Scott , Raul Perez-Olle , David W Andrews Neuro-Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
